regulators
FDA places no penalties on Novartis after Zolgensma data manipulation investigation
April 2, 2020Business Services FDA, Novartis, regulators
The FDA has concluded its investigation into Novartis and its data manipulation of the gene therapy Zolgensma, and has decided …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
